|
Companies' Sessions
|
|
|
Novartis (Visudyne)
|
|
| |
|
Current
and future trends in CNV management
Chairperson: J. Mones |
Back
to
Section List page |
| |
|
| |
Introduction of co-chair and
panel
J. Monés |
|
| |
|
|
| |
From early innovation to current
experience - the case for Visudyne therapy
U. Schmidt-Erfurth |
|
| |
|
|
 |
Refining management of CNV
due to AMD - maximising patient benefit through prompt
and appropriate treatment (case studies with Visudyne
and placebo)
J. Monés |
|
| |
|
|
| |
Continuing innovation with Visudyne - combination with triamcinolone: interesting insight
P. Kaiser |
|
| |
|
|
| |
Visudyne: case study examples
G. Soubrane |
|
| |
|
|
| |
Lucentis: a novel antiangiogenic
therapy for CNV in AMD
L. Damico |
|
| |
|
|
| |
Lucentis: results from phase
I/II studies
P. Rosenfeld |
|
| |
|
|
| |
Questions from the audience
G. Soubrane and J. Mones |
|
| |
|
